Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Lux Health Tech Acquisition (LUXAU)
Upcoming IPO
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Atlas Crest Investment Corp. (ACICU)
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Bluescape Opportunities Acquisition (BOAC.U)
Absolute Software (ABST)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

ALX Oncology Holdings Inc. (ALXO)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Cancer cells leverage CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. Their company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. They believe their lead product candidate, ALX148, will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. They have dosed over 150 subjects with ALX148 across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. They intend to advance ALX148 into clinical development for the treatment of myelodysplastic syndromes, or MDS, acute myeloid leukemia, or AML, and to continue clinical development for the treatment of a range of solid tumor indications. Based on their clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability and their clinical development plans, their strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Jaume Pons Peter Garcia
Employees Founded
24 2015

Contacts

Address: 866 Malcolm Road, Suite 100 Burlingame, CA 94010, US

Telephone: 650-466-7125

Web page: http://alxoncology.com

IPO information

Expected Date 7/17/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $555.4
Revenues (MM) $4.4
Net Income (Loss) (MM) $-25.6

Voting

What do you think will happen with the ALXO share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 8
Shares Revised (MM) 8.5
Expected offer amount (MM) $128
Realized offer amount(MM) $161.5
Underwriters
Jefferies/ Credit Suisse/ Piper Sandler/ Cantor
CO-Managers
LifeSci Capital

Sector: Healthcare

Tweets about $ALXO

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats